LEQSELVI Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving LEQSELVI Growth

• FDA Approval Created a New Commercial Opportunity in Severe Alopecia Areata

LEQSELVI received US FDA approval in July 2024 for the treatment of adults with severe alopecia areata (AA), becoming one of a limited number of systemic therapies approved for this autoimmune hair-loss disorder. The approval provides Sun Pharma access to a sizeable underserved market; according to the company, approximately 700,000 people in the US have alopecia areata, including about 300,000 with severe disease. This large untreated population represents a significant growth opportunity for the brand.

• Strong Phase III Efficacy Supporting Physician Adoption

LEQSELVI demonstrated robust efficacy in the pivotal THRIVE-AA1 and THRIVE-AA2 Phase III trials involving approximately 1,220 patients with severe alopecia areata. Sun Pharma reported that patients had an average of only 13% scalp hair coverage at baseline, and by Week 24, approximately one-third of treated patients achieved at least 80% scalp hair coverage. The statistically significant results across two large registrational studies strengthen physician confidence and support broader uptake in dermatology practices.

• Differentiated JAK1/JAK2 Mechanism and Convenient Oral Administration

LEQSELVI is a selective oral JAK1/JAK2 inhibitor administered as an oral tablet twice daily. Alopecia areata is driven by immune-mediated attack on hair follicles, and JAK inhibition directly targets pathways implicated in disease pathogenesis. The convenience of oral administration, combined with clinically meaningful hair regrowth outcomes, enhances its attractiveness relative to older off-label treatment approaches.

• Durability of Response and Long-Term Clinical Data

Beyond the initial approval studies, Sun Pharma presented data showing that patients treated with LEQSELVI for up to 68 weeks continued to experience meaningful improvements in scalp hair regrowth. Long-term durability is particularly important in alopecia areata, where sustained efficacy is a major consideration for physicians and patients. Durable responses can support higher treatment persistence and recurring revenue generation.

• Strategic Importance Within Sun Pharma's Specialty Dermatology Portfolio

Sun Pharma has identified specialty dermatology as a major growth engine for its US business. Management has committed substantial commercial investment behind specialty products, including LEQSELVI. The company's established dermatology infrastructure and relationships with dermatologists should facilitate market penetration and payer engagement, accelerating adoption following launch. Analysts have also highlighted LEQSELVI as an important contributor to future specialty-business growth.

LEQSELVI Recent Developments

In March 2026, The Medicines and Healthcare products Regulatory Agency (MHRA) approved deuruxolitinib (LEQSELVI) from Sun Pharma UK Ltd. to treat severe alopecia areata in adults. Approval was based on two pivotal clinical trials. The trials studied 1223 adult patients with alopecia areata that had lost at least 50% of their hair for more than 6 months. In both trials, subjects received twice daily either Leqselvi 8 mg, deuruxolitinib 12 mg or a placebo for 24 weeks. After 24 weeks, the patients that received Leqselvi scored higher on a scale used to measure scalp hair than those that received the placebo. Leqselvi was shown to improve hair growth in subjects with severe alopecia areata, with around 30% of subjects experiencing 80% or more scalp hair after 24 weeks of treatment, and around 23% of subjects experiencing 90% or more scalp hair after 24 weeks of treatment. The most common side effects with deuruxolitinib (which may affect more than 1 in 10 people) are headache and acne.

“LEQSELVI Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of LEQSELVI for approved indication like Alopecia areata in the 7MM. A detailed picture of LEQSELVI’s existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the LEQSELVI for approved indications. The LEQSELVI market report provides insights about LEQSELVI’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current LEQSELVI performance, future market assessments inclusive of the LEQSELVI market forecast analysis for approved indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of LEQSELVI sales forecasts, along with factors driving its market.

LEQSELVI Drug Summary

LEQSELVI (generic name: Deuruxolitinib) is an oral, selective Janus kinase (JAK) 1 and JAK2 inhibitor developed by Sun Pharmaceutical Industries Ltd. for the treatment of severe Alopecia Areata in adults. Administered as an oral tablet, deuruxolitinib works by inhibiting JAK-mediated signaling pathways involved in the autoimmune attack on hair follicles, thereby helping restore normal hair growth. The drug demonstrated significant efficacy in the pivotal THRIVE-AA1 and THRIVE-AA2 Phase III clinical trials, where a substantially higher proportion of patients achieved meaningful scalp hair regrowth compared with placebo. LEQSELVI offers a targeted, non-steroidal treatment option for patients with severe alopecia areata and has shown a generally manageable safety profile consistent with the JAK inhibitor class, making it an important addition to the growing landscape of therapies for autoimmune hair loss. The report provides LEQSELVI’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the LEQSELVI Market Report

The report provides insights into:

• A comprehensive product overview including the LEQSELVI MoA, description, dosage and administration, research and development activities in approved indication like Alopecia areata.
• Elaborated details on LEQSELVI regulatory milestones and other development activities have been provided in LEQSELVI market report.
• The report also highlights LEQSELVI‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The LEQSELVI market report also covers the patents information, generic entry and impact on cost cut.
• The LEQSELVI market report contains current and forecasted LEQSELVI sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The LEQSELVI market report also features the SWOT analysis with analyst views for LEQSELVI in approved indications.

Methodology

The LEQSELVI market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LEQSELVI Analytical Perspective

• In-depth LEQSELVI Market Assessment

This LEQSELVI sales market forecast report provides a detailed market assessment of LEQSELVI for approved indication like Alopecia areata in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted LEQSELVI sales data uptil 2034.

• LEQSELVI Clinical Assessment

The LEQSELVI market report provides the clinical trials information of LEQSELVI for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.

LEQSELVI Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

LEQSELVI Market Potential & Revenue Forecast

• Projected market size for the LEQSELVI and its key indications
• Estimated LEQSELVI sales potential (LEQSELVI peak sales forecasts)
• LEQSELVI Pricing strategies and reimbursement landscape

LEQSELVI Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• LEQSELVI Market positioning compared to existing treatments
• LEQSELVI Strengths & weaknesses relative to competitors

LEQSELVI Regulatory & Commercial Milestones

• LEQSELVI Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

LEQSELVI Clinical Differentiation

• LEQSELVI Efficacy & safety advantages over existing drugs
• LEQSELVI Unique selling points

LEQSELVI Market Report Highlights

• In the coming years, the LEQSELVI market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The LEQSELVI companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LEQSELVI’s dominance.
• Other emerging products for Alopecia areata are expected to give tough market competition to LEQSELVI and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LEQSELVI in approved indications.
• Analyse LEQSELVI cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted LEQSELVI sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of LEQSELVI in approved indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of LEQSELVI? How strong is LEQSELVI’s clinical and commercial performance?
• What is LEQSELVI’s clinical trial status in each individual indications such as Alopecia areata and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LEQSELVI Manufacturers?
• What are the key designations that have been granted to LEQSELVI for approved indications? How are they going to impact LEQSELVI’s penetration in various geographies?
• What is the current and forecasted LEQSELVI market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of LEQSELVI in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to LEQSELVI for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is LEQSELVI? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.